查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620760

一次電池市場：按產地、電池類型和最終用戶分類 - 2025-2030 年全球預測

Primary Cells Market by Origin (Animal Primary Cells, Human Primary Cells), Cell Type (Dermatocytes, Gastrointestinal Cells, Heart Cells), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年一次電池市值為14.3億美元，預計到2024年將達到16億美元，複合年成長率為12.10%，預計到2030年將達到31.8億美元。

由於一次電池在電池生理學研究和生命科學藥物開發中的重要作用，一次電池市場正在顯著擴大。一次電池直接從活體組織中收集並保留其原始功能和基因，因此它們對於比電池庫存更嚴肅的生物研究至關重要。需求範圍從模擬體內條件到生物醫學研究、藥物發現和組織工程的相關性。應用範圍廣泛，包括癌症研究、心血管研究和神經科學，最終用戶主要是研究機構、製藥公司和生物技術公司。生物技術的進步、對個人化醫療的日益關注以及政府對電池研究的資助增加是影響該市場成長的關鍵因素。快速成長的再生醫學領域帶來了龐大的商機，一次電池成為開發新型治療候選藥物的關鍵要素。然而，分離和維護電池的高昂成本，以及對動物和人類電池來源的道德擔憂，為市場成長帶來了挑戰。 3D 電池培養和 CRISPR 基因編輯等創新有可能帶來突破，並為研究人員提供更具成本效益和更有效率的工具。對公司來說，投資這些領域以保持競爭力將是有利的。多中心研究合作以及與學術機構的夥伴關係可以透過匯集資源和知識來幫助克服一些限制，從而擴大目前的應用並加速發展。創新的關鍵部分之一是創建標準化且價格實惠的原電池菌株，可減少變異性並提高研究結果的可重複性。市場是充滿活力和競爭的，公司必須不斷適應新的科學發現和技術進步，以保持該領域的成長和相關性。

主要市場統計
基準年[2023] 14.3億美元
預計年份 [2024] 16億美元
預測年份 [2030] 31.8億美元
複合年成長率（%） 12.10%

市場動態：揭示一次電池

供需的動態互動正在改變一次電池市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大藥物篩檢和電池檢測的接受度
    • 與其他現有方法相比，第一代體細胞的優勢
    • 對單株抗體和個人化醫療的興趣日益濃厚
  • 市場限制因素
    • 常見的電池文化問題，例如污染
  • 市場機會
    • 生物技術和生物製藥產業的擴張
    • 一次電池生物醫學研究進展
  • 市場問題
    • 電池生物學研究領域的倫理問題

波特五力：駕馭一次電池市場的策略工具

波特五力框架是了解一次電池市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對一次電池市場的影響

外部宏觀環境因素對一次電池市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解一次電池市場競爭狀況

對一次電池市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣：一次電池市場廠商績效評估

FPNV定位矩陣是評估一次電池市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製一次電池市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，一次電池市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 藥物篩檢和電池檢測的普及
      • 與現有方法相比，人類原代細胞的優勢
      • 單株抗體和個人化醫療日益受到關注
    • 抑制因素
      • 常見的電池文化問題，例如污染
    • 機會
      • 生物技術和生物製藥產業的擴張
      • 使用一次電池的生物醫學研究進展
    • 任務
      • 電池生物學研究領域的倫理問題
  • 市場區隔分析
    • 起源：人們越來越傾向於使用人類一次電池來準確地表示人類電池反應
    • 電池類型：在藥物開發和毒理學測試中擴大採用皮膚電池
    • 最終用戶：生命科學公司使用一次電池的數量激增，以確保實驗過程中獲得準確的結果
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章一次電池市場：依來源分類

  • 介紹
  • 動物
  • 人類

第7章一次電池市場：依電池類型

  • 介紹
  • 皮膚電池
  • 胃腸電池
  • 心臟電池
  • 造血電池
  • 肝臟電池
    • 凍存肝電池
    • 新鮮肝臟電池
  • 肺電池
  • 肌肉骨骼電池
  • 腎臟電池

第8章一次電池市場：依最終用戶分類

  • 介紹
  • 生命科學公司
  • 研究所

第9章 北美、南美一次電池市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太一次電池市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲一次電池市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • CN Bio 和 LifeNet Health LifeSciences 合作為微生理學系統提供檢驗的第一代體細胞
    • AnaBios 收購 Cell Systems 以擴大用於藥物發現的人體電池產品組合
    • Human Cell Design 推出 Endoc-BH5，這是一種先進的人類 BETA 細胞模型，可為 1 型和 2 型糖尿病研究帶來新發現
  • 戰略分析和建議

公司名單

  • Biopredic International
  • Corning Incorporated
  • Danaher Corporation
  • FUJIFILM Irvine Scientific, Inc.
  • Lonza AG
  • PromoCell GmbH
  • Reachbio LLC
  • Sciencell Research Laboratories, Inc.
  • Sekisui Xenotech, LLC
  • Stem Cell Technologies, Inc.
  • StemExpress, LLC
  • The Bio Convergence Company
  • The Merck Group
  • Thermo Fisher Scientific, Inc.
  • Zenbio, Inc.
Product Code: MRR-4F4C36263622

The Primary Cells Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.60 billion in 2024, and is projected to grow at a CAGR of 12.10%, to USD 3.18 billion by 2030.

The market for primary cells is expanding significantly, driven by their essential role in life sciences for studying cellular physiology and drug development. Primary cells are directly obtained from living tissues, retaining native functions and genetics, which makes them indispensable for more authentic biological research compared to cell lines. Their necessity spans across biomedical research, drug discovery, and tissue engineering due to their relevance in mimicking in vivo conditions. Applications are extensive including cancer research, cardiovascular studies, and neuroscience, with end-users predominantly comprising research institutes, pharmaceutical companies, and biotechnology firms. Key growth influencers in the primary cells market include advancements in biotechnology, a heightened focus on personalized medicine, and increasing government funding for cell-based research. The burgeoning field of regenerative medicine presents substantial opportunities, with primary cells serving as a crucial component for developing novel therapeutic candidates. However, market growth is challenged by the high costs of cell isolation and maintenance and the ethical concerns regarding animal and human-derived cell sources. Technological innovations such as 3D cell cultures and CRISPR gene editing could provide breakthroughs, offering more cost-effective and efficient tools for researchers. It would be beneficial for companies to invest in these areas to stay competitive. Multi-center collaborations and partnerships with academic institutions can help overcome some limitations by pooling resources and knowledge, thus expanding the current applications and expediting development. One of the key areas for innovation is in creating standardized and affordable primary cell lines that can reduce variability and enhance reproducibility of research outcomes. The market is dynamic and competitive, requiring businesses to stay adaptive to new scientific discoveries and technological advancements to maintain growth and relevance in the field.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.60 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 12.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Primary Cells Market

The Primary Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing acceptance in drug screening and cell based assays
    • Advantages of primary human cells over other existing methods
    • Growing focus on monoclonal antibodies and personalized medicine
  • Market Restraints
    • Common cell culture problems such as contamination
  • Market Opportunities
    • Expanding biotechnology and biopharmaceutical industries
    • Advancements in biomedical research using primary cells
  • Market Challenges
    • Ethical issues in cell biology research field

Porter's Five Forces: A Strategic Tool for Navigating the Primary Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Primary Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Primary Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Primary Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Primary Cells Market

A detailed market share analysis in the Primary Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Primary Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Primary Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Primary Cells Market

A strategic analysis of the Primary Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Origin, market is studied across Animal Primary Cells and Human Primary Cells.
  • Based on Cell Type, market is studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.
  • Based on End-User, market is studied across Life Science Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing acceptance in drug screening and cell based assays
      • 5.1.1.2. Advantages of primary human cells over other existing methods
      • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Common cell culture problems such as contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
      • 5.1.3.2. Advancements in biomedical research using primary cells
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues in cell biology research field
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
    • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
    • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Primary Cells Market, by Origin

  • 6.1. Introduction
  • 6.2. Animal Primary Cells
  • 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. Dermatocytes
  • 7.3. Gastrointestinal Cells
  • 7.4. Heart Cells
  • 7.5. Hematopoietic Cells
  • 7.6. Hepatocytes
    • 7.6.1. Cryopreserved Hepatocytes
    • 7.6.2. Fresh Hepatocytes
  • 7.7. Lung Cells
  • 7.8. Musculoskeletal Cells
  • 7.9. Renal Cells

8. Primary Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Life Science Companies
  • 8.3. Research Institutes

9. Americas Primary Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Primary Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
    • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
    • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biopredic International
  • 2. Corning Incorporated
  • 3. Danaher Corporation
  • 4. FUJIFILM Irvine Scientific, Inc.
  • 5. Lonza AG
  • 6. PromoCell GmbH
  • 7. Reachbio LLC
  • 8. Sciencell Research Laboratories, Inc.
  • 9. Sekisui Xenotech, LLC
  • 10. Stem Cell Technologies, Inc.
  • 11. StemExpress, LLC
  • 12. The Bio Convergence Company
  • 13. The Merck Group
  • 14. Thermo Fisher Scientific, Inc.
  • 15. Zenbio, Inc.

LIST OF FIGURES

  • FIGURE 1. PRIMARY CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. PRIMARY CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRIMARY CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRIMARY CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023